Scheduling is not the main source of legal risk in the botanical supplement market, and it never has been. Nearly every federal enforcement action ever taken against a kratom or 7-OH seller in the United States happened while the substance was completely unscheduled. Those cases were brought under the Federal Food, Drug, and Cosmetic Act, which runs on a separate track from controlled-substance law and applies to everything on a supplement shelf regardless of whether anything is scheduled.
This matters because a lot of buyers and retailers are treating August 5, 2026 as the moment risk begins. It is more accurate to say that scheduling adds a new criminal layer on top of exposure that has existed continuously for a decade.
Quick Answer: FDA's Enforcement Toolkit
| Tool | What it is | Who it reaches |
|---|---|---|
| Warning letter | Public letter identifying violations, typically demanding a written response within 15 business days | Manufacturers, wholesalers, importers, online sellers, retail entities |
| Import alert | Detention without physical examination at the border; the importer must affirmatively prove compliance | Importers and anyone whose supply chain crosses a border |
| Seizure | A court action against the goods themselves, executed by US Marshals | Whoever physically holds the product, including distribution warehouses |
| Injunction or consent decree | Court order restricting or halting operations, often with ongoing oversight | The firm and frequently its officers by name |
| Criminal referral | Investigation by FDA's Office of Criminal Investigations, prosecuted by DOJ | Companies and individuals, including owners of small operations |
Two Systems, Not One
Controlled-substance law asks whether a molecule appears on a schedule. Food and drug law asks an entirely different question: whether the article is a lawful food, supplement or drug, whether its label is truthful, and whether the ingredient in it is permitted in that format at all.
An article can be perfectly unscheduled and still be unlawful to sell. That is not a technicality — it is the basis of virtually the entire enforcement record in this category, including the largest seizures.
The Four Legal Theories
Unapproved new drug
An article becomes a "drug" not because of what is in it but because of what it is intended for, and intent is proved objectively from the seller's own expressions: labeling, advertising, statements by the company or its representatives, the product's design, and the circumstances of distribution. Once an article is a drug, it needs an approved application, and without one the product is simultaneously misbranded for lacking adequate directions for use. Two violations from one sentence of copy.
The bar is lower than most sellers assume. In a 2022 joint action with the FTC against four online retailers, the agency treated third-party website content and a reposted social media message as the retailer's own therapeutic claim. You own what you amplify.
Misbranding
A label is misbranded if it is false or misleading in any particular. There is no materiality threshold and no intent element built into the basic prohibition. Ingredient declarations, supplement facts formatting and accurate quantity statements are all separate hooks.
Adulteration
Three independent routes. An added deleterious substance is one. The food-additive route is a second, and it is badly underappreciated: if the format is a conventional food — a drink, a shot, a gummy, a chew — rather than a labeled supplement, the ingredient needs an authorizing food-additive regulation or GRAS status. Format alone can move a product out of the supplement framework into a regime where the ingredient is unlawful per se. The third route runs through new dietary ingredients.
New dietary ingredient
This is the workhorse. If an ingredient was not marketed in the United States as a dietary ingredient before October 15, 1994, it is a new dietary ingredient and requires a premarket notification with safety substantiation. No notification on file means the product is adulterated automatically, as a matter of paperwork. It does not matter how safe the ingredient actually is, and it does not matter what the seller knew. This is why FDA can act against products that have caused no reported harm at all.
Warning Letters Are a Record, Not a Request
A warning letter is not a court order, and receiving one is not a finding of liability. It is also not nothing. It is public, permanent, indexed by search engines, and it establishes the agency's position and the date the recipient learned of it. If enforcement escalates later, the letter is the document that converts "we did not know" into a much harder argument.
The June 2025 letters to seven firms, announced the following month, are the clearest illustration of who gets targeted. The recipients were not all manufacturers. The set deliberately included a wholesaler, an importer that also sold online, and an entity with "Retail" in its legal name. For two of those recipients, escalation actually happened: a December 2025 seizure took roughly 73,000 units worth about a million dollars out of two distribution warehouses.
Import Alerts Shift the Burden
An import alert authorizes detention without physical examination. In ordinary practice the government must show a product is violative; under an alert the presumption flips, and the importer must affirmatively demonstrate that a shipment is compliant before it enters.
The knock-on effect reaches beyond importers. An import alert becomes a predicate for other charges — several criminal cases in this space were built on importing merchandise contrary to law, where the underlying law was the FDA alert rather than any drug statute. Shipments described on customs paperwork as incense, paint pigment or soil conditioner produced felony convictions and multi-million-dollar forfeitures.
Seizures Reach Whoever Is Holding the Goods
A seizure is an action against the property itself. It does not require proving that any person did anything knowingly, and it lands on whoever physically possesses the inventory. The record in this category runs from roughly 25,000 pounds taken from a distributor in 2014 through a series of actions against bottled products, brand owners and warehouses in 2016, 2021, 2023 and 2025.
One detail from the 2014 case is worth carrying forward. The product was labeled "not for human consumption" and sold as potpourri. The government aggregated content from affiliated websites to establish intended use, and won. Disclaimers do not survive contact with the rest of your marketing.
Criminal Exposure and the FTC's Parallel Track
FDA's Office of Criminal Investigations refers cases to DOJ. The basic FD&C offense is a strict-liability misdemeanor; it becomes a felony where there is intent to defraud or mislead, or on a repeat offense. Prosecutors also reach for adjacent statutes — importing contrary to law, conspiracy to defraud the United States, money laundering where supplier payments are involved.
The most instructive case for this market involved a sports-supplement company whose label described a synthetic stimulant as a natural plant extract and which produced false certificates of analysis. Two executives received five-year and two-year prison sentences. Neither ingredient in that case was ever a controlled substance. The offense was lying about composition.
Separately, the FTC polices advertising substantiation and deception, and works jointly with FDA in this category. An efficacy claim you cannot substantiate is an FTC problem even where it is not an FDA problem.
The Distribution Tier Is Not a Bystander
"We only resell it" has very little support in the enforcement record. The statute prohibits the receipt in interstate commerce of an adulterated or misbranded food and its delivery for pay. You do not have to manufacture it, formulate it or write the label. Buying it and offering it for sale is the conduct the provision describes.
There is one boundary worth knowing. A pure reseller of another company's finished, sealed product sits largely outside manufacturer-level obligations. The moment a distributor's own name goes on the label — private label, house brand, relabeled bulk — it inherits full manufacturing responsibilities including setting specifications and verifying ingredient identity. Outsourcing production has never transferred that responsibility.
What Actually Reduces Risk
- Structure and function language only. No claims to treat, cure, prevent, diagnose or mitigate anything, and no implying the reader has a condition.
- Watch what you link, repost and allow. Affiliate copy, influencer posts and customer testimonials you republish can all be attributed to you.
- Know your ingredient's regulatory status, not just its scheduling status. These are different questions with different answers.
- Keep supplier documentation. Names, addresses, delivery records, and written assurances from the supplier about the article's status.
- Never make a negative claim broader than your test panel. This one deserves emphasis.
That last point is the center of our own approach, and it cuts against ordinary marketing instinct. An affirmative negative claim is a representation you own, and it is falsifiable by a single lab result. It converts an omission into an affirmative misstatement, which is precisely the fact pattern that produced prison sentences in the case above.
So we say exactly this: the supplier certificates we hold report non-detect for 7-hydroxymitragynine, mitragynine, speciociliatine, speciogynine, paynantheine, corynantheidine and mitraphylline. Those panels do not test for mitragynine pseudoindoxyl, MGM-15, MGM-16 or corynoxine B. We therefore say nothing about those four compounds, and a seller who tells you their product has been cleared of every compound named in the scheduling action is making a claim their paperwork almost certainly cannot support. You can read the certificates yourself on our COA page, and our guide to reading a COA explains how to spot the difference between a compound tested and cleared and a compound never examined.
Why This Shapes How We Operate
We are a distributor and retailer. We do not manufacture, formulate or private-label anything — we carry other companies' brands and we screen what we stock. That means our exposure runs almost entirely through two things: what we choose to carry, and what we say about it. Our screening process is described in how we vet brands, and the reasoning behind the language limits we impose on ourselves is in what non-detect actually means. The full terms we publish are on our disclaimer page, and the range itself is in the cat's claw collection.
Frequently Asked Questions
Can FDA act against a product that is completely legal?
Yes, and it routinely does. Scheduling and food-and-drug status are separate questions. An unscheduled ingredient can still be an unlawful new dietary ingredient, an unapproved food additive, or the subject of a misbranded label.
Does a warning letter mean a company is guilty of something?
No. It states the agency's position and requests a response. It is not a court finding. It is public and permanent, and it establishes what the recipient knew and when, which matters a great deal if anything escalates.
Am I safe if I make no health claims at all?
Silence removes the largest single risk, and the enforcement record contains no criminal prosecution of a pure pass-through retailer who made no therapeutic claims and committed no labeling or import fraud. That is a genuine finding and worth stating plainly. It is an absence of evidence rather than a guarantee, and it does not address adulteration or new-dietary-ingredient theories, which do not depend on claims at all.
Does an LLC protect the owner?
Partially and unreliably. Individual officers have been named in FD&C cases, state consumer-protection suits and tort actions, and personal participation in packing, shipping or accepting payment is regularly pleaded. This is worth a conversation with a lawyer rather than an assumption.
What changes after August 5, 2026?
Controlled-substance liability is added to everything described above; none of it is replaced. We cover the scheduling side in DEA temporary scheduling explained.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. For adults 21+. Legality depends on the specific formulation and applicable state law — check the rules where you live. Nothing here is legal advice.